Iberdomide

• Background:

  Iberdomide is a modulator of the cullin ring ligase 4-cereblon E3 ubiquitin ligase complex with higher affinity (IC50 = 60 nM) than lenalidomide and pomalidomide leading to more potent degradation of Ikaros (IKZF1; EC50 = 1 nM) ) and Aiolos (IKZF3; EC50 = 0.5 nM) .1 It is more specific for the cereblon complex and does not degrade GSPT1 of CK1α. It displays antitumor and immunostimulatory activity in lenalidomide- and pomalidomide-resistant multiple myeloma cells.2 Iberdomide has also shown efficacy in treating the autoimmune disease cutaneous lupus erythematosus (CLE) .3 It was also shown to act as an HIV-1 latency reversal agent in in CD4+ T-cells.4

• Conjugation:

  Unconjugated

• Buffer:

  White solid

• Storage Conditions:

  -20°C